Imaging the Invisible: Granzyme B and the Future of Immunotherapy Monitoring with Guest Dr. Ben Larimer

As a scientist, innovator, and CEO of CytoSite BioPharma, Dr. Ben Larimer has reshaped how we think about imaging immune response in cancer. His work on Granzyme B PET imaging is unlocking unprecedented insights into whether—and where—immunotherapies are working inside the body.In this episode of Fractals, Ben joins host Colin Miller to discuss:The origins of Granzyme B imaging and what makes it a uniquely powerful imaging agent.How CytoSite’s imaging agent revealed success in preclinical models—and sparked a new clinical path forward.The balance between scientific innovation and real-world biotech execution.Why PET imaging’s future depends on AI, cost reduction, and deeper diagnostic precision.Tune into Fractals: Life Science Conversations wherever you get your podcasts—and contact Bracken to learn how we help imaging agents move from molecule to market.